Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | PYGB | P11216 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19946 | 0.98 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL16429773 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| D-Mannose SCHEMBL1772795 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| D-Galactose SCHEMBL17593535 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Dextrose SCHEMBL6038162 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Beta-D-Glucose SCHEMBL361597 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL361515 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Dextrose SCHEMBL7651668 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL361340 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL361799 | 0.78 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304734-A1 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304734-A1 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | MAN2A1, ALG1, MNS1 | LGALS1 317/4885LGALS3 975/4885LGALS9 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.